ScripChina’s first homegrown vaccine for herpes zoster (shingles), Ganwei, developed by Changchun BCHT Biotechnology Co. (BCHT), had a strong commercial launch in 2023, setting the stage for a showdown w
ScripJune marked the busiest month for initial public offerings of innovative drug-focused biotechs on the Shanghai and Hong Kong stock exchanges during the whole of the first half of 2023. In Shanghai, an
ScripShares of Beijing Luzhu Biopharmaceutical Co Ltd (Luzhu Biotech) were listed on the Hong Kong Stock Exchange on 8 May, making the Chinese developer of vaccines and monoclonal and bispecific antibodi
ScripTwo Chinese biotechs developing recombinant herpes zoster vaccines have garnered support from venture capital and private equity firms by raising a combined more than CNY700m ($104m) over the past few